Medlab Clinical Ltd (ASX: MDC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medlab Clinical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.07 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.28 million
Earnings per share
-1.714
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medlab Clinical Ltd (ASX: MDC)
Latest News
Healthcare Shares
Why is the Medlab (ASX:MDC) share price surging 8% today?
Share Market News
Here's why the Medlab (ASX:MDC) share price is rising today
Share Gainers
Why Clean TeQ, Medlab, Newcrest, & Ramelius are storming higher today
Share Gainers
Why this ASX cannabis share is shooting 15% higher today
Share Gainers
Why THC Global and these ASX cannabis shares are rocketing higher today
52-Week Highs
Why this ASX biotech is printing 52-week highs
Share Gainers
This small-cap ASX biotech's share price is soaring today
Share Gainers
Why Medlab, Metcash, SKY and Space Global, and WiseTech shares charged higher today
Share Market News
These small cap ASX shares are on the rise today
⏸️ Investing
Is Medlab Clinical Ltd the best small cap healthcare buy on the ASX?
⏸️ Investing
Why these pot stocks are moving higher
⏸️ Investing
Why shares of Medlab Clinical Ltd have risen 37% in 2018
1❯
MDC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medlab Clinical Ltd
Medlab Clinical Ltd is an Australian biotechnology company that specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals to empower patients with chronic diseases and mental health conditions and enhance their lives.. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B, and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Matthew John Hudson | Non-Executive Director | Mar 2023 |
Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy, which operates 43 oil and gas wells across Kansas and Oklahoma. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
|
| Mr Sean Michael Hall | Chief Executive Officer | Apr 2014 |
Mr Hall has over 20 years of experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's practitioner brand, BioCeuticals. Dr Hall is a member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
|
| Mr Tim Walker | Non-Executive Director | Mar 2024 |
Mr Walker has experience in originating, managing, and leading a variety resource transaction. Specifically, in M&A transactions across the Canadian and Australian markets, IPOs, and both equity and debt financing solutions. Tims past directorships with exploration companies have provided him a experience across various commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
|
| Mr Edmond Tan | Non-Executive Director | Mar 2024 |
Mr Tan has 10 years experience in various roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a specific focus on foreign investment into Australia. Currently, Edmond is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
|
| Mr Kerem Kaya | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
| Kerem Kaya | Chief Financial OfficerCompany Secretary |
-
|
|
| David Rutolo | Director of Science |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| No top 20 shareholder's information disclosed | 0 | 0.00% |
